This book is a detailed guide to therapy response imaging in cancer patients that fully takes into account the revolutionary progress and paradigm shift in treatment approaches for advanced disease. The opening chapters describe the role of imaging as a “common language” for tumor response evaluation in oncology and address challenges and strategies in the era of precision cancer therapy and cancer immunotherapy. Practical pitfalls are discussed, with emphasis on the importance of approaching cancer as a systemic disease and the need for increased awareness of drug toxicity due to novel therapies. Therapy response imaging in a wide range of cancer types is then comprehensively described and illustrated, using a disease-specific approach. A concluding section focuses on emerging approaches and future directions, including radiomics/radiogenomics, co-clinical imaging, and molecular and functional imaging. Therapy Response Imaging in Oncology will be of high value for radiologists, nuclear medicine physicians, and oncologists. It will also be of interest to cancer care providers and oncology trial investigators.

Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion. A companion website includes the full text and an image bank.

This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology.

Completely updated to reflect the latest developments in science and technology, the second edition of this reference presents the diagnostic imaging tools essential to the detection, diagnosis, staging, treatment planning, and post-treatment management of cancer in both adults and children. Organized by major organs and body systems, the text offers comprehensive, abundantly illustrated guidance to enable both the radiologist and clinical oncologist to better appreciate and overcome the challenges of tumor imaging. Features 12 brand-new chapters that examine new imaging techniques, molecular imaging, minimally invasive approaches, 3D and conformal treatment planning, interventional techniques in radiation oncology, interventional breast techniques, and more. Emphasizes practical interactions between oncologists and radiologists. Includes expanded coverage of paediatric tumours as well as thorax, gastrointestinal tract, genitourinary, and musculoskeletal cancers. Offers reorganized and increased content on the brain and spinal cord. Nearly 1,400 illustrations enable both the radiologist and clinical oncologist to better appreciate and overcome the challenges of tumour imaging. - Outstanding Features! Presents internationally renowned authors' insights on recent technological breakthroughs in imaging for each anatomical region, and offers their views on future advances in the field. Discusses the latest advances in treatment planning. Devotes four chapters to the critical role of imaging in radiation treatment planning and delivery. Makes reference easy with a body-system organisation.

This open access book focuses on diagnostic and interventional imaging of the chest, breast, heart, and vessels. It consists of a remarkable collection of contributions authored by internationally respected experts, featuring the most recent diagnostic developments and technological advances with a highly didactical approach. The chapters are disease-oriented and cover all the relevant imaging modalities, including standard radiography, CT, nuclear medicine with PET, ultrasound and magnetic resonance imaging, as well as imaging-guided interventions. As such, it presents a comprehensive review of current knowledge on imaging of the heart and chest, as well as thoracic interventions and a selection of "hot topics". The book is intended for radiologists, however, it is also of interest to clinicians in oncology, cardiology, and pulmonology.

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.